Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 144
Filtrar
Mais filtros

Intervalo de ano de publicação
1.
Photodiagnosis Photodyn Ther ; 45: 103928, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38070633

RESUMO

BACKGROUND: The treatment of acne vulgaris is often challenging due to the antibiotic resistance frequently observed in Cutibacterium acnes (C.acnes), a prevalent bacterium linked to this condition. OBJECTIVE: The objective of this research was to examine the impact of curcumin photodynamic therapy (PDT) on the survival of C.acnes and activity of biofilms produced by this microorganism. METHODS: Following the Clinical and Laboratory Standards Institute (CLSI) guidelines, we assessed the drug sensitivity of 25 clinical C.acnes strains to five antibiotics (erythromycin, clindamycin, tetracycline, doxycycline, minocycline) and curcumin by implementing the broth microdilution technique. In addition, we established C.acnes biofilms in a laboratory setting and subjected them to curcumin-PDT(curcumin combined with blue light of 180 J/cm2). Afterwards, we evaluated their viability using the XTT assay and observed them using confocal laser scanning microscopy. RESULTS: The result revealed varying resistance rates among the tested antibiotics and curcumin, with erythromycin, clindamycin, tetracycline, doxycycline, minocycline, and curcumin exhibiting resistance rates of 72 %, 44 %, 36 %, 28 %, 0 %, and 100 %, respectively. In the curcumin-PDT inhibition tests against four representative antibiotic-resistant strains, it was found that the survival rate of all strains of planktonic C. acnes was reduced, and the higher the concentration of curcumin, the lower the survival rate. Furthermore, in the biofilm inhibition tests, the vitality and three-dimensional structure of the biofilms were disrupted, and the inhibitory effect became more significant with higher concentrations of curcumin. CONCLUSION: The results emphasize the possibility of using curcumin PDT as an alternative approach for the treatment of C.acnes, especially in instances of antibiotic-resistant variations and infections related to biofilms.


Assuntos
Acne Vulgar , Curcumina , Fotoquimioterapia , Humanos , Clindamicina/farmacologia , Clindamicina/uso terapêutico , Doxiciclina/farmacologia , Doxiciclina/uso terapêutico , Curcumina/farmacologia , Curcumina/uso terapêutico , Minociclina/farmacologia , Minociclina/uso terapêutico , Testes de Sensibilidade Microbiana , Fármacos Fotossensibilizantes/farmacologia , Fármacos Fotossensibilizantes/uso terapêutico , Fotoquimioterapia/métodos , Acne Vulgar/tratamento farmacológico , Antibacterianos/uso terapêutico , Eritromicina/farmacologia , Eritromicina/uso terapêutico , Tetraciclina/farmacologia , Tetraciclina/uso terapêutico , Biofilmes , Propionibacterium acnes
2.
Mol Cell Probes ; 66: 101874, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-36400114

RESUMO

The perturbation of gut microbiome is a risk factor for a number of adverse conditions. Among other factors antibiotic therapy is a common culprit. We characterized the short-term alteration of gut microbiome after antibiotic therapy. Nine patients (age (median [range]): 67 [57-75 years]) were subjected to prostate biopsy. Ciprofloxacin and clindamycin, 500 mg and 150 mg, respectively, were administered twice a day; this combination therapy was started the day before and continued until 5th and 8th day, respectively, following biopsy. 16s RNA sequencing data from fecal swabs taken before antibiotic therapy and 14 days after biopsy were analysed. At phylum level, the abundance of Actinobacteria and Firmicutes decreased, while that of Bacteroides and Proteobacteria increased after antibiotic therapy. The ratio of Firmicutes:Bacteroides inversed (from 2.81 to 0.74, p = 0.035). At order level, the abundance of Bacteroidales and Veillonellales increased, while that of Clostridiales and Coriobacteriales decreased. At genus level the abundance of Bacteroides increased, while those of Roseburia, Faecalibacterium and Collinsella decreased. These findings indicate that short-term antibiotic exposure skews gut microbiome composition. The current level of knowledge does not allow to decide whether this skewness is detrimental and has any long-term effect on disease including prostate pathology.


Assuntos
Clindamicina , Microbioma Gastrointestinal , Masculino , Humanos , Clindamicina/uso terapêutico , Ciprofloxacina/uso terapêutico , Antibacterianos/uso terapêutico , Próstata , Biópsia
3.
Front Cell Infect Microbiol ; 12: 883798, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35646743

RESUMO

Background: The diagnosis and treatment of mixed vaginitis are more complicated than single pathogenic infections, and there may be adverse reactions and several contraindications to conventional antibiotic therapy. Therefore, this study aimed to evaluate the preliminary effects of Fufang Furong Effervescent Suppository for the management of aerobic vaginitis (AV) mixed with bacterial vaginosis (BV) using Accurate 16S absolute quantification sequencing (Accu16S). Methods: In the present randomized, blind, multi-center clinical trial, women (20 to 55 years) who had received a diagnosis of AV+BV were randomly assigned into clindamycin positive control (n = 41) and Fufang Furong Effervescent Suppository (n = 39) groups. The follow-up occurred in three time periods (V1: -2~0 days; V2: 15-17 days; V3: 40 ± 3 days). At each visit, two vaginal swabs, one for clinical evaluation and one for laboratory examination, were taken from each patient. The Nugent score, Donders' score, drug-related complications, recurrence rates, and microecological changes of vaginal swabs were assessed in the time three periods. Results: At baseline, the two groups were similar in frequency of presentation with vaginal burning, odor, abnormal discharge, and itching. No meaningful differences in Nugent and Donders' scores were detected between the two groups at stage V2 (Nugent: p = 0.67; Donders': p = 0.85) and V3 (Nugent: p = 0.97; Donders: p = 0.55). The Furong group presented fewer complications compared to the Clindamycin group. However, this difference was not statistically significant (p = 0.15). Additionally, Accu16S indicated that the total abundance of bacteria in both groups sharply decreased in stage V2, but slightly increased in V3. In stage V3, the absolute abundance of Lactobacillus in the Furong group was considerably higher compared to untreated samples (p < 0.05). On the other hand, no momentous increase was detected in the Clindamycin group (p > 0.05). Conclusion: Fufang Furong Effervescent Suppository can be as effective as clindamycin cream in the management of AV+BV while may restore the vagina microecosystem better.


Assuntos
Vaginite , Vaginose Bacteriana , Vulvovaginite , Clindamicina/uso terapêutico , Feminino , Humanos , Vagina/microbiologia , Vaginite/diagnóstico , Vaginite/tratamento farmacológico , Vaginite/microbiologia , Vaginose Bacteriana/diagnóstico , Vaginose Bacteriana/tratamento farmacológico , Vaginose Bacteriana/microbiologia
4.
Anaerobe ; 69: 102348, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-33596468

RESUMO

OBJECTIVES: Eggerthella lenta is a Gram-positive anaerobic bacillus that is an important cause of bloodstream infections. This study aims to test the susceptibility of Eggerthella lenta blood culture isolates to commonly used antibiotics for the empirical treatment of anaerobic infections. METHODS: In total, 49 positive blood cultures for Eggerthella lenta were retrospectively included from patients hospitalised at the Universitair Ziekenhuis Brussel, Belgium, between 2004 and 2018. Identification was done by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) system. Antimicrobial susceptibility testing was performed using the reference agar dilution method according to Clinical and Laboratory Standards Institute (CLSI) guidelines with Brucella agar supplemented with 5 µg/mL hemin, 1 µg/mL vitamin K1 and 5% laked sheep blood. The minimal inhibitory concentrations were interpreted using the EUCAST breakpoints. Clinical characteristics were collected by reviewing the patient's medical records. RESULTS: All isolates were susceptible to amoxicillin-clavulanate, metronidazole and meropenem. Eighty-eight % of them were susceptible to clindamycin and 94% (20% S, 74% I) were susceptible to piperacillin-tazobactam. The mean age of the patients was 64 (±20) and they showed a 30-day mortality of 27%. The source of infection was in 65.3% of the cases abdominal, 20.4% were sacral pressure ulcers and 14.3% were unknown causes. While all isolates were fully susceptible at standard dosing regimen to amoxicillin-clavulanate, most were only susceptible at increased exposure or resistant to piperacillin-tazobactam. CONCLUSIONS: Our results suggest to be careful with the use of piperacillin-tazobactam and clindamycin in the empirical treatment of Eggerthella lenta infections.


Assuntos
Actinobacteria/efeitos dos fármacos , Actinobacteria/isolamento & purificação , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Bactérias Anaeróbias/isolamento & purificação , Sangue/microbiologia , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico , Bélgica , Clindamicina/uso terapêutico , Feminino , Bactérias Gram-Positivas/efeitos dos fármacos , Bactérias Gram-Positivas/isolamento & purificação , Hospitais Universitários/estatística & dados numéricos , Humanos , Masculino , Meropeném/uso terapêutico , Metronidazol/uso terapêutico , Pessoa de Meia-Idade , Combinação Piperacilina e Tazobactam/uso terapêutico , Estudos Retrospectivos
5.
J Postgrad Med ; 67(1): 36-38, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33533750

RESUMO

Glyphosate is the most commonly used broad-spectrum, non-selective herbicide in the world. The toxicity is supposed to be due to uncoupling of oxidative phosphorylation and the surfactant polyoxyethylene amine (POEA)- mediated cardiotoxicity. Clinical features of this herbicide poisoning are varied, ranging from asymptomatic to even death. There is no antidote and aggressive supportive therapy is the mainstay of treatment for glyphosate poisoning. We present a 69-year-old female patient with suicidal consumption of around 500 ml of Glycel®. Initially, gastric lavage was done and intravenous fluids were given. Within two hours of presentation, the patient developed respiratory distress needing intubation, hypotension needing vasopressor support, and severe lactic acidosis. She also developed acute respiratory distress syndrome, hypokalemia, hypernatremia, and aspiration pneumonia. Our patient was critically ill with multiple poor prognostic factors, but with timely aggressive supportive management, the patient gradually recovered.


Assuntos
Glicina/análogos & derivados , Herbicidas/intoxicação , Hipernatremia/etiologia , Hipopotassemia/etiologia , Pneumonia Aspirativa/etiologia , Síndrome do Desconforto Respiratório/etiologia , Idoso , Cefamandol/administração & dosagem , Cefamandol/análogos & derivados , Cefamandol/uso terapêutico , Cefoperazona/administração & dosagem , Cefoperazona/uso terapêutico , Clindamicina/administração & dosagem , Clindamicina/uso terapêutico , Suplementos Nutricionais , Feminino , Glicina/intoxicação , Humanos , Hipernatremia/tratamento farmacológico , Hipopotassemia/tratamento farmacológico , Pneumonia Aspirativa/tratamento farmacológico , Potássio/administração & dosagem , Potássio/uso terapêutico , Síndrome do Desconforto Respiratório/tratamento farmacológico , Tentativa de Suicídio , Sulbactam/administração & dosagem , Sulbactam/uso terapêutico , Resultado do Tratamento
6.
J Dermatolog Treat ; 32(2): 197-202, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-31760846

RESUMO

BACKGROUND: Acne is the most prevalent skin disease in the world and antibiotics as its standard treatments have limited and also adverse effects. Cedar (Ziziphus spina-christi) has medicinal properties like antibacterial activity and is used topically for treatment of some kinds of skin problems in Persian medicine. The aim of this study was to evaluation the efficacy of topical cedar solution of acne vulgaris. METHODS: Eighty patients aged between 15-45 years with mild to moderate acne vulgaris were conducted in this randomized, double blind trial. The participants were allocated to receive the topical cedar solution plus clindamycin 1% or topical placebo plus 1% clindamycin solution for six weeks. Patients were evaluated at the beginning of the study, second, sixth and eighth weeks after intervention for the acne severity index (ASI) and total acne lesions counting (TLC). Data was analyzed by SPSS software with Mann-Whitney U test. RESULTS: From 105 subjects 68 people completed the study (33 persons in cedar group and 35 persons in placebo group). The mean and standard deviation of the age was 26.1 ± 7.5 years and 22 subjects (32.4%) were male. TLC and ASI in the sixth and eighth weeks in cedar group were significantly less than in placebo group (p < 0.001). Topical cedar solution had no serious side effects. CONCLUSION: The topical cedar solution plus clindamycin 1% was more effective and safe than placebo plus 1% clindamycin for the treatment of acne vulgaris.


Assuntos
Acne Vulgar/tratamento farmacológico , Extratos Vegetais/uso terapêutico , Acne Vulgar/patologia , Administração Tópica , Adolescente , Adulto , Antibacterianos/uso terapêutico , Clindamicina/análogos & derivados , Clindamicina/uso terapêutico , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Efeito Placebo , Extratos Vegetais/química , Índice de Gravidade de Doença , Resultado do Tratamento , Adulto Jovem , Ziziphus/química , Ziziphus/metabolismo
7.
J Infect Dis ; 223(2): 319-325, 2021 02 03.
Artigo em Inglês | MEDLINE | ID: mdl-32697310

RESUMO

BACKGROUND: Inhalational anthrax is rare and clinical experience limited. Expert guidelines recommend treatment with combination antibiotics including protein synthesis-inhibitors to decrease toxin production and increase survival, although evidence is lacking. METHODS: Rhesus macaques exposed to an aerosol of Bacillus anthracis spores were treated with ciprofloxacin, clindamycin, or ciprofloxacin + clindamycin after becoming bacteremic. Circulating anthrax lethal factor and protective antigen were quantitated pretreatment and 1.5 and 12 hours after beginning antibiotics. RESULTS: In the clindamycin group, 8 of 11 (73%) survived demonstrating its efficacy for the first time in inhalational anthrax, compared to 9 of 9 (100%) with ciprofloxacin, and 8 of 11 (73%) with ciprofloxacin + clindamycin. These differences were not statistically significant. There were no significant differences between groups in lethal factor or protective antigen levels from pretreatment to 12 hours after starting antibiotics. Animals that died after clindamycin had a greater incidence of meningitis compared to those given ciprofloxacin or ciprofloxacin + clindamycin, but numbers of animals were very low and no definitive conclusion could be reached. CONCLUSION: Treatment of inhalational anthrax with clindamycin was as effective as ciprofloxacin in the nonhuman primate. Addition of clindamycin to ciprofloxacin did not enhance reduction of circulating toxin levels.


Assuntos
Antraz/sangue , Antraz/prevenção & controle , Antígenos de Bactérias/sangue , Bacillus anthracis/efeitos dos fármacos , Bacillus anthracis/fisiologia , Toxinas Bacterianas/sangue , Ciprofloxacina/uso terapêutico , Clindamicina/uso terapêutico , Infecções Respiratórias/sangue , Infecções Respiratórias/prevenção & controle , Animais , Antraz/microbiologia , Antraz/mortalidade , Antibacterianos/uso terapêutico , Biomarcadores , Ciprofloxacina/farmacologia , Clindamicina/farmacologia , Modelos Animais de Doenças , Quimioterapia Combinada , Macaca mulatta , Prognóstico , Infecções Respiratórias/microbiologia , Infecções Respiratórias/mortalidade , Resultado do Tratamento
8.
Cochrane Database Syst Rev ; 9: CD012871, 2020 09 24.
Artigo em Inglês | MEDLINE | ID: mdl-32970845

RESUMO

BACKGROUND: Preterm birth (PTB) remains the foremost global cause of perinatal morbidity and mortality. Thus, the prevention of spontaneous PTB still remains of critical importance. In an attempt to prevent PTB in singleton pregnancies, cervical cerclage, in combination with other treatments, has been advocated. This is because, cervical cerclage is an intervention that is commonly recommended in women with a short cervix at high risk of preterm birth but, despite this, many women still deliver prematurely, as the biological mechanism is incompletely understood. Additionally, previous Cochrane Reviews have been published on the effectiveness of cervical cerclage in singleton and multiple pregnancies, however, none has evaluated the effectiveness of using cervical cerclage in combination with other treatments. OBJECTIVES: To assess whether antibiotics administration, vaginal pessary, reinforcing or second cerclage placement, tocolytic, progesterone, or other interventions at the time of cervical cerclage placement prolong singleton gestation in women at high risk of pregnancy loss based on prior history and/or ultrasound finding of 'short cervix' and/or physical examination. History-indicated cerclage is defined as a cerclage placed usually between 12 and 15 weeks gestation based solely on poor prior obstetrical history, e.g. multiple second trimester losses due to painless dilatation. Ultrasound-indicated cerclage is defined as a cerclage placed usually between 16 and 23 weeks gestation for transvaginal ultrasound cervical length < 20 mm in a woman without cervical dilatation. Physical exam-indicated cerclage is defined as a cerclage placed usually between 16 and 23 weeks gestation because of cervical dilatation of one or more centimetres detected on physical (manual) examination. SEARCH METHODS: We searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) (26 September 2019), and reference lists of retrieved studies. SELECTION CRITERIA: We included published, unpublished or ongoing randomised controlled trial (RCTs). Studies using a cluster-RCT design were also eligible for inclusion in this review but none were identified. We excluded quasi-RCTs (e.g. those randomised by date of birth or hospital number) and studies using a cross-over design. We also excluded studies that specified addition of the combination therapy after cervical cerclage because the woman subsequently became symptomatic. We included studies comparing cervical cerclage in combination with one, two or more interventions with cervical cerclage alone in singleton pregnancies. DATA COLLECTION AND ANALYSIS: Two review authors independently screened titles and abstracts of all retrieved articles, selected studies for inclusion, extracted data, assessed risk of bias, and evaluated the certainty of the evidence for this review's main outcomes. Data were checked for accuracy. Standard Cochrane review methods were used throughout. MAIN RESULTS: We identified two studies (involving a total of 73 women) comparing cervical cerclage alone to a different comparator. We also identified three ongoing studies (one investigating vaginal progesterone after cerclage, and two investigating cerclage plus pessary). One study (20 women), conducted in the UK, comparing cervical cerclage in combination with a tocolytic (salbutamol) with cervical cerclage alone in women with singleton pregnancy did not provide any useable data for this review. The other study (involving 53 women, with data from 50 women) took place in the USA and compared cervical cerclage in combination with a tocolytic (indomethacin) and antibiotics (cefazolin or clindamycin) versus cervical cerclage alone - this study did provide useable data for this review (and the study authors also provided additional data on request) but meta-analyses were not possible. This study was generally at a low risk of bias, apart from issues relating to blinding. We downgraded the certainty of evidence for serious risk of bias and imprecision (few participants, few events and wide 95% confidence intervals). Cervical cerclage in combination with an antibiotic and tocolytic versus cervical cerclage alone (one study, 50 women/babies) We are unclear about the effect of cervical cerclage in combination with antibiotics and a tocolytic compared with cervical cerclage alone on the risk of serious neonatal morbidity (RR 0.62, 95% CI 0.31 to 1.24; very low-certainty evidence); perinatal loss (data for miscarriage and stillbirth only - data not available for neonatal death) (RR 0.46, 95% CI 0.13 to 1.64; very low-certainty evidence) or preterm birth < 34 completed weeks of pregnancy (RR 0.78, 95% CI 0.44 to 1.40; very low-certainty evidence). There were no stillbirths (intrauterine death at 24 or more weeks). The trial authors did not report on the numbers of babies discharged home healthy (without obvious pathology) or on the risk of neonatal death. AUTHORS' CONCLUSIONS: Currently, there is insufficient evidence to evaluate the effect of combining a tocolytic (indomethacin) and antibiotics (cefazolin/clindamycin) with cervical cerclage compared with cervical cerclage alone for preventing spontaneous PTB in women with singleton pregnancies. Future studies should recruit sufficient numbers of women to provide meaningful results and should measure neonatal death and numbers of babies discharged home healthy, as well as other important outcomes listed in this review. We did not identify any studies looking at other treatments in combination with cervical cerclage. Future research needs to focus on the role of other interventions such as vaginal support pessary, reinforcing or second cervical cerclage placement, 17-alpha-hydroxyprogesterone caproate or dydrogesterone or vaginal micronised progesterone, omega-3 long chain polyunsaturated fatty acid supplementation and bed rest.


Assuntos
Cerclagem Cervical/métodos , Nascimento Prematuro/prevenção & controle , Albuterol/uso terapêutico , Analgésicos Opioides/uso terapêutico , Antibacterianos/uso terapêutico , Viés , Cefazolina/uso terapêutico , Clindamicina/uso terapêutico , Feminino , Humanos , Indometacina/uso terapêutico , Ópio/uso terapêutico , Gravidez , Nascimento Prematuro/epidemiologia , Ensaios Clínicos Controlados Aleatórios como Assunto , Natimorto/epidemiologia , Tocolíticos/uso terapêutico
9.
Artigo em Inglês | MEDLINE | ID: mdl-31964789

RESUMO

Clostridioides difficile infection (CDI) is a health care-associated infection associated with significant morbidity and cost, with highly varied risk across populations. More effective, risk-based prevention strategies are needed. Here, we investigate risk factors for hospital-associated CDI in a large integrated health system. In a retrospective cohort of all adult admissions to 21 Intermountain Healthcare hospitals from 2006 to 2012, we identified all symptomatic (i) hospital-onset and (ii) health care-facility-associated, community-onset CDI. We then evaluated the risk associated with antibiotic exposure, including that of specific agents, using multivariable logistic regression. A total of 2,356 cases of CDI among 506,068 admissions were identified (incidence, 46.6 per 10,000). Prior antibiotic use was the dominant risk factor, where for every antibiotic day of therapy prior to the index admission, the odds of subsequent CDI increased by 12.8% (95% confidence interval [CI], 12.2 to 13.4%; P < 0.0001). This was a much stronger association than was inpatient antibiotic exposure (odds ratio [OR], 1.007 [95% CI, 1.005 to 1.009]; P < 0.0001). The highest-risk antibiotics included second-generation and later cephalosporins (especially oral), carbapenems, fluoroquinolones, and clindamycin, while doxycycline and daptomycin were associated with a lower CDI risk. We concluded that cumulative antibiotic exposure prior to admission is the greatest contributor to the risk of subsequent CDI. Most classes of antibiotics carry some risk, which varies by drug and route. This information may be useful for antimicrobial stewardship efforts.


Assuntos
Adaptação Fisiológica/efeitos dos fármacos , Antibacterianos/efeitos adversos , Gestão de Antimicrobianos , Clostridioides difficile/efeitos dos fármacos , Infecções por Clostridium/tratamento farmacológico , Infecção Hospitalar/microbiologia , Adaptação Fisiológica/genética , Antibacterianos/uso terapêutico , Carbapenêmicos/efeitos adversos , Carbapenêmicos/uso terapêutico , Cefalosporinas/efeitos adversos , Cefalosporinas/uso terapêutico , Clindamicina/efeitos adversos , Clindamicina/uso terapêutico , Clostridioides difficile/genética , Infecção Hospitalar/induzido quimicamente , Infecção Hospitalar/tratamento farmacológico , Daptomicina/efeitos adversos , Daptomicina/uso terapêutico , Doxiciclina/efeitos adversos , Doxiciclina/uso terapêutico , Farmacorresistência Bacteriana/genética , Feminino , Fluoroquinolonas/efeitos adversos , Fluoroquinolonas/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
10.
G Ital Dermatol Venereol ; 155(6): 749-753, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30249083

RESUMO

BACKGROUND: Over recent years, the link between obesity, metabolic syndrome and Hidradenitis suppurativa (HS) has been explored. It has been demonstrated that HS patients have a high prevalence of the metabolic syndrome and an increased frequency of insulin resistance. The objective of our study is to estimate the effectiveness of an oral supplementation based on myo-inositol (MI), folic acid and liposomal magnesium (Levigon®, Sanitpharma; Milan, Italy) on the clinical and metabolic profile of patients affected by HS. METHODS: Twenty subjects with HS and an impaired glucose metabolism were enrolled. Group A: 10 subjects received for 6 months MI 2000 mg, liposomal magnesium and folic acid associated to topical antibiotic therapy (clindamycin gel 1%), systemic antibiotic therapy (clindamycin 300 mg b.i.d. and rifampicin 600 mg daily for 6 weeks) and a normocaloric diet group B: 10 subjects received topical and systemic antibiotic therapy associated to a normocaloric diet for 6 months. RESULTS: After 6 months group A patients showed an average reduction of Sartorius Score from 38.3±7.75 to 27.3±13.53 (P value <0.04) while in the control group there was a reduction of the Sartorius from 38.4±7.88 to 31.1±8.02 (P value =0.55). Moreover in group A Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was significantly reduced from 2.43±0.35 to 2.1±0.31 (P<0.01) whereas in group B HOMA-IR did not significantly decrease (2.51±0.65 at T0 at 2.40±0.67 at T1). CONCLUSIONS: Our study underlines the importance of the evaluation of metabolic profile in patients with HS. Moreover, it suggests that the supplementation of MI, folic acid and liposomal magnesium in HS can improve the efficacy of concomitant therapies and the metabolic profile.


Assuntos
Suplementos Nutricionais , Intolerância à Glucose/complicações , Hidradenite Supurativa/tratamento farmacológico , Administração Cutânea , Administração Oral , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Clindamicina/administração & dosagem , Clindamicina/uso terapêutico , Combinação de Medicamentos , Quimioterapia Combinada , Ingestão de Energia , Ácido Fólico/administração & dosagem , Ácido Fólico/uso terapêutico , Intolerância à Glucose/dietoterapia , Hidradenite Supurativa/complicações , Hidradenite Supurativa/epidemiologia , Hidradenite Supurativa/metabolismo , Humanos , Inositol/administração & dosagem , Inositol/uso terapêutico , Resistência à Insulina , Lipossomos , Magnésio/administração & dosagem , Magnésio/uso terapêutico , Síndrome Metabólica/complicações , Síndrome Metabólica/dietoterapia , Prevalência , Rifampina/administração & dosagem , Rifampina/uso terapêutico , Índice de Gravidade de Doença
11.
J Eur Acad Dermatol Venereol ; 33 Suppl 6: 28-31, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31535767

RESUMO

Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory disease associated with a high physical and psychological burden. It is a disorder of the infundibular segment of the pilosebaceous unit, characterized by subcutaneous nodules, abscesses, sinus tracts and scar formation on the intertriginous and apocrine-bearing areas. HS is quite rare in young and prepubertal children. It usually begins after puberty, but several reports of prepubertal HS onset have been described. These cases are strongly linked to hormonal disorders and genetic susceptibility. Specific guidelines for prepubertal patients are still lacking, so further studies are warranted to better delineate a tailored approach. This paper aims to summarize the most significant aspects, as well as the most recent information about the epidemiology, pathogenesis, clinical features, diagnosis, comorbidities and treatment of paediatric HS. In addition, we report our clinical experience in managing HS in a group of eight prepubertal patients based on systemic antibiotics (azithromycin) and zinc oral supplementation.


Assuntos
Antibacterianos/uso terapêutico , Hidradenite Supurativa/tratamento farmacológico , Azitromicina/uso terapêutico , Criança , Clindamicina/uso terapêutico , Quimioterapia Combinada , Feminino , Predisposição Genética para Doença , Hidradenite Supurativa/complicações , Hidradenite Supurativa/epidemiologia , Hidradenite Supurativa/genética , Humanos , Hiperandrogenismo/complicações , Hiperinsulinismo/complicações , Guias de Prática Clínica como Assunto , Puberdade Precoce/complicações
12.
Rev Esp Quimioter ; 32(4): 327-332, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31271277

RESUMO

OBJECTIVE: Several studies have reported greater success of fertilisation by ART in couples who were not infected by Ureaplasma. Increased semen quality and better results have also been observed in couples who were treated with antibiotics to eradicate the infection. The aim of this study was to determine the prevalence of genital mycoplasmas in urine samples from male partners enrolled in the Assisted Reproduction Program (ARP) in our healthcare area so that, positive cases can be treated prior to the use of ART in order to increase the quality of semen, improve the embryo implantation rates and minimize the risk of adverse effects during pregnancy. METHODS: This study included couples enrolled in the ARP during 2016. Mycoplasma detection was made using real-time PCR. In positive cases, both members of the couple were treated with antibiotics until eradication of the microorganism. The antibiotics used were: azithromycin, doxycycline, levofloxacin, moxifloxacin, and clindamycin. RESULTS: Of the 205 men studied, 33 were positive: Ureaplasma urealyticum 15.1%, Mycoplasma hominis 3.9%. Eradication treatment with azithromycin failed in 50% compared to 10.2% for doxycycline. Of the 5 cases treated with levofloxacin, only 2 achieved elimination of U. urealyticum. CONCLUSIONS: We consider that genital mycoplasma routine screening could be useful in order to increase the quality of semen which could simplify the in vitro fertilisation procedures and raise the success rate of embryo implantation and pregnancy, especially when fast, sensitive and specific technics as real time PCR are used.


Assuntos
Antibacterianos/uso terapêutico , Doenças dos Genitais Masculinos/tratamento farmacológico , Infecções por Mycoplasma/tratamento farmacológico , Técnicas de Reprodução Assistida , Análise do Sêmen , Adulto , Azitromicina/uso terapêutico , Clindamicina/uso terapêutico , Doxiciclina/uso terapêutico , Implantação do Embrião , Feminino , Doenças dos Genitais Femininos/tratamento farmacológico , Doenças dos Genitais Femininos/epidemiologia , Doenças dos Genitais Femininos/microbiologia , Doenças dos Genitais Masculinos/epidemiologia , Doenças dos Genitais Masculinos/microbiologia , Doenças dos Genitais Masculinos/urina , Humanos , Levofloxacino/uso terapêutico , Masculino , Pessoa de Meia-Idade , Moxifloxacina/uso terapêutico , Infecções por Mycoplasma/epidemiologia , Infecções por Mycoplasma/urina , Mycoplasma hominis/efeitos dos fármacos , Mycoplasma hominis/genética , Mycoplasma hominis/isolamento & purificação , Prevalência , Reação em Cadeia da Polimerase em Tempo Real , Fatores Sexuais , Resultado do Tratamento , Infecções por Ureaplasma/tratamento farmacológico , Infecções por Ureaplasma/epidemiologia , Infecções por Ureaplasma/urina , Ureaplasma urealyticum/efeitos dos fármacos , Ureaplasma urealyticum/genética , Ureaplasma urealyticum/isolamento & purificação , Adulto Jovem
13.
PLoS One ; 14(2): e0211888, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30735536

RESUMO

BACKGROUND: Empiric antibiotic therapy for suspected hematogenous vertebral osteomyelitis (HVO) should be initiated immediately in seriously ill patients and may be required in those with negative microbiological results. The aim of this study was to inform the appropriate selection of empiric antibiotic regimens for the treatment of suspected HVO by analyzing antimicrobial susceptibility of isolated bacteria from microbiologically proven HVO. METHOD: We conducted a retrospective chart review of adult patients with microbiologically proven HVO in five tertiary-care hospitals over a 7-year period. The appropriateness of empiric antibiotic regimens was assessed based on the antibiotic susceptibility profiles of isolated bacteria. RESULTS: In total, 358 cases of microbiologically proven HVO were identified. The main causative pathogens identified were methicillin-susceptible Staphylococcus aureus (33.5%), followed by methicillin-resistant S. aureus (MRSA) (24.9%), Enterobacteriaceae (19.3%), and Streptococcus species (11.7%). Extended spectrum ß-lactamase (ESBL)-producing Enterobacteriaceae and anaerobes accounted for only 1.7% and 1.4%, respectively, of the causative pathogens. Overall, 73.5% of isolated pathogens were susceptible to levofloxacin plus rifampicin, 71.2% to levofloxacin plus clindamycin, and 64.5% to amoxicillin-clavulanate plus ciprofloxacin. The susceptibility to these oral combinations was lower in cases of healthcare-associated HVO (52.6%, 49.6%, and 37.6%, respectively) than in cases of community-acquired HVO (85.8%, 84.0%, and 80.4%, respectively). Vancomycin combined with ciprofloxacin, ceftriaxone, ceftazidime, or cefepime was similarly appropriate (susceptibility rates of 93.0%, 94.1%, 95.8%, and 95.8%, respectively). CONCLUSIONS: Based on our susceptibility data, vancomycin combined with a broad-spectrum cephalosporin or fluoroquinolone may be appropriate for empiric treatment of HVO. Fluoroquinolone-based oral combinations may be not appropriate due to frequent resistance to these agents, especially in cases of healthcare-associated HVO.


Assuntos
Antibacterianos/uso terapêutico , Infecções Bacterianas/tratamento farmacológico , Enterobacteriaceae/efeitos dos fármacos , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Osteomielite/tratamento farmacológico , Streptococcus/efeitos dos fármacos , Idoso , Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico , Infecções Bacterianas/diagnóstico , Infecções Bacterianas/microbiologia , Infecções Bacterianas/patologia , Ciprofloxacina/uso terapêutico , Clindamicina/uso terapêutico , Quimioterapia Combinada , Pesquisa Empírica , Enterobacteriaceae/crescimento & desenvolvimento , Enterobacteriaceae/patogenicidade , Feminino , Expressão Gênica , Humanos , Levofloxacino/uso terapêutico , Masculino , Staphylococcus aureus Resistente à Meticilina/crescimento & desenvolvimento , Staphylococcus aureus Resistente à Meticilina/patogenicidade , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Osteomielite/diagnóstico , Osteomielite/microbiologia , Osteomielite/patologia , Estudos Retrospectivos , Rifampina/uso terapêutico , Coluna Vertebral/efeitos dos fármacos , Coluna Vertebral/microbiologia , Coluna Vertebral/patologia , Streptococcus/crescimento & desenvolvimento , Streptococcus/patogenicidade , Vancomicina/uso terapêutico , beta-Lactamases/genética , beta-Lactamases/metabolismo
14.
J Am Acad Dermatol ; 80(5): 1314-1321, 2019 May.
Artigo em Inglês | MEDLINE | ID: mdl-30502416

RESUMO

BACKGROUND: Antibiotics are recognized as first-line treatments for hidradenitis suppurativa (HS), but the data on their efficacy are limited. OBJECTIVE: Evaluate the efficacy of oral clindamycin versus that of clindamycin plus rifampicin in patients with HS. METHODS: A total of 60 patients with mild-to-moderate-severe HS who were classified according to their International Hidradenitis Suppurativa Severity Score System (IHS4) and Hurley scores, were subdivided into 2 groups of 30 patients each (group A, the members of which received clindamycin plus rifampicin, and group B, the members of which were treated with clindamycin alone) and retrospectively studied. The main objective was to evaluate and compare the clinical and ultrasound responses between the groups after 8 weeks of treatment according to the Hidradenitis Suppurativa Clinical Response measure. RESULTS: After the treatment, 17 of 30 patients in group A and 19 of 30 in group B met the primary outcome. Both groups showed a similar improvement of IHS4 score, whereas the Dermatology Life Quality Index and pain Visual Analogue Scale scores improved more in group B. In particular, the reductions in nodule and abscess counts were similar between the 2 groups, whereas the number of draining tunnels decreased more in group B. The factors significantly associated with Hidradenitis Suppurativa Clinical Response score were age, body mass index, IHS4 score, and absence of axillary involvement. Disease-free survival was similar between the 2 groups. LIMITATIONS: The study was not randomized or placebo-controlled. CONCLUSION: Clindamycin may be a useful treatment alternative to antibiotic combination regardless of HS clinical stage.


Assuntos
Antibacterianos/uso terapêutico , Clindamicina/uso terapêutico , Hidradenite Supurativa/tratamento farmacológico , Rifampina/uso terapêutico , Adolescente , Adulto , Fatores Etários , Índice de Massa Corporal , Intervalo Livre de Doença , Quimioterapia Combinada , Feminino , Hidradenite Supurativa/complicações , Hidradenite Supurativa/diagnóstico por imagem , Humanos , Masculino , Pessoa de Meia-Idade , Dor/etiologia , Qualidade de Vida , Estudos Retrospectivos , Índice de Gravidade de Doença , Resultado do Tratamento , Ultrassonografia , Adulto Jovem
15.
J Pharmacol Sci ; 137(1): 12-19, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29769163

RESUMO

Dauricine, isolated from Menispermum dauricum, has been widely used for treatment of various diseases, including cardiac ischemia and inflammation-related diseases. However, little is known regarding to the effect of dauricine on severe pneumonia. Therefore, the aim was to investigate the effect of dauricine on severe pneumonia and its mechanism during progress. Herein, H5N1 and Streptococcus pneumoniae (D39) were conducted to induce severe pneumonia in both BEAS-2B cells and mice. In vitro, dauricine reversed the protein and mRNA expressions of TNF-α, IL-6 and IL-1ß, examined by ELISA and qRT-PCR assay, respectively. In addition, the nuclear translocation of NF-κB/p65 and the phosphorylation expressions of IκBα and IKKα/ß, examined by western blotting, were dose-dependently dropped by dauricine. However, dauricine had no significant effect on MAPKs, including JNK, ERK and p38. In vivo, dauricine significantly decreased MPO activity, the lung wet/dry weight ratio, the protein and mRNA expression of TNF-α, IL-6 and IL-1ß, the expressions of NF-κB/p65, and attenuated the lung histological alterations. Besides, compared to dauricine alone, combined with clindamycin had more remarkably effects on severe pneumonia in vitro. Overall, the results suggested that dauricine, a relatively drug that targets NF-κB, in combination with clindamycin, maybe a novel therapeutic strategy for severe pneumonia.


Assuntos
Benzilisoquinolinas/uso terapêutico , Clindamicina/uso terapêutico , Coinfecção/tratamento farmacológico , Virus da Influenza A Subtipo H5N1 , Fitoterapia , Pneumonia/tratamento farmacológico , Transdução de Sinais/efeitos dos fármacos , Streptococcus pneumoniae , Tetra-Hidroisoquinolinas/uso terapêutico , Animais , Benzilisoquinolinas/isolamento & purificação , Células Cultivadas , Coinfecção/microbiologia , Cães , Quimioterapia Combinada , Feminino , Humanos , Menispermum/química , Camundongos Endogâmicos BALB C , Terapia de Alvo Molecular , NF-kappa B/metabolismo , Pneumonia/microbiologia , Índice de Gravidade de Doença , Tetra-Hidroisoquinolinas/isolamento & purificação
16.
Artigo em Inglês | MEDLINE | ID: mdl-29661872

RESUMO

Treatment of anthrax is challenging, especially during the advanced stages of the disease. Recently, the Centers for Disease Control and Prevention (CDC) updated its recommendations for postexposure prophylaxis and treatment of exposed populations (before and after symptom onset). These recommendations distinguished, for the first time, between systemic disease with and without meningitis, a common and serious complication of anthrax. The CDC considers all systemic cases meningeal unless positively proven otherwise. The treatment of patients suffering from systemic anthrax with suspected or confirmed meningitis includes the combination of three antibiotics, i.e., a fluoroquinolone (levofloxacin or ciprofloxacin), a ß-lactam (meropenem or imipenem), and a protein synthesis inhibitor (linezolid or clindamycin). In addition, treatment with an antitoxin (anti-protective antigen antibodies) and dexamethasone should be applied. Since the efficacy of most of these treatments has not been demonstrated, especially in animal meningitis models, we developed an anthrax meningitis model in rabbits and tested several of these recommendations. We demonstrated that, in this model, ciprofloxacin, linezolid, and meropenem were ineffective as single treatments, while clindamycin was highly effective. Furthermore, combined treatments of ciprofloxacin and linezolid or ciprofloxacin and dexamethasone failed in treating rabbits with meningitis. We demonstrated that dexamethasone actually hindered blood-brain barrier penetration by antibiotics, reducing the effectiveness of antibiotic treatment of anthrax meningitis in this rabbit model.


Assuntos
Antraz/tratamento farmacológico , Antibacterianos/uso terapêutico , Antitoxinas/uso terapêutico , Bacillus anthracis/efeitos dos fármacos , Meningites Bacterianas/tratamento farmacológico , Animais , Antraz/patologia , Sistema Nervoso Central/microbiologia , Sistema Nervoso Central/patologia , Ciprofloxacina/uso terapêutico , Clindamicina/uso terapêutico , Dexametasona/uso terapêutico , Modelos Animais de Doenças , Combinação de Medicamentos , Imipenem/uso terapêutico , Levofloxacino/uso terapêutico , Linezolida/uso terapêutico , Meningites Bacterianas/microbiologia , Meningites Bacterianas/patologia , Meropeném/uso terapêutico , Coelhos , Falha de Tratamento
17.
BMC Vet Res ; 13(1): 116, 2017 Apr 28.
Artigo em Inglês | MEDLINE | ID: mdl-28454567

RESUMO

BACKGROUND: Antimicrobial resistance in staphylococci, often associated with treatment failure, is increasingly reported in veterinary medicine. The aim of this study was to investigate patterns and predictors of antimicrobial resistance among Staphylococcus spp. isolates from canine samples submitted to the bacteriology laboratory at the University of Pretoria academic veterinary hospital between 2007 and 2012. Retrospective data of 334 Staphylococcus isolates were used to calculate the proportion of samples resistant to 15 antimicrobial agents. The Cochran-Armitage trend test was used to investigate temporal trends and logistic regression models were used to investigate predictors of antimicrobial resistance in Staphylococcus aureus and Staphylococcus pseudintermedius. RESULTS: Results show that 98.2% (55/56) of the S. aureus isolates were resistant to at least one drug while 42.9% were multidrug resistant. Seventy-seven percent (214/278) of the S. pseudintermedius isolates were resistant to at least one drug and 25.9% (72/278) were multidrug resistant. Resistance to lincospectin was more common among S. aureus (64.3%) than S. pseudintermedius (38.9%). Similarly, resistance to clindamycin was higher in S. aureus (51.8%) than S. pseudintermedius (31.7%) isolates. There was a significant (p = 0.005) increase in S. aureus resistance to enrofloxacin over the study period. Similarly, S. pseudintermedius exhibited significant increasing temporal trend in resistance to trimethoprim-sulphamethoxazole (p = 0.004), clindamycin (p = 0.022) and orbifloxacin (p = 0.042). However, there was a significant decreasing temporal trend in the proportion of isolates resistant to doxycycline (p = 0.041), tylosin (p = 0.008), kanamycin (p = 0.017) and amoxicillin/clavulanic acid (p = 0.032). CONCLUSIONS: High levels of multidrug resistance and the increasing levels of resistance to sulphonamides, lincosamides and fluoroquinolones among Staphylococcus spp. isolates in this study are concerning. Future studies will need to investigate local drivers of antimicrobial resistance to better guide control efforts to address the problem.


Assuntos
Antibacterianos/uso terapêutico , Doenças do Cão/microbiologia , Infecções Estafilocócicas/veterinária , Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico , Animais , Ciprofloxacina/análogos & derivados , Ciprofloxacina/uso terapêutico , Clindamicina/uso terapêutico , Doenças do Cão/tratamento farmacológico , Doenças do Cão/epidemiologia , Cães , Doxiciclina/uso terapêutico , Farmacorresistência Bacteriana , Farmacorresistência Bacteriana Múltipla , Enrofloxacina , Feminino , Fluoroquinolonas/uso terapêutico , Hospitais Veterinários/estatística & dados numéricos , Canamicina/uso terapêutico , Lincomicina/uso terapêutico , Masculino , Estudos Retrospectivos , África do Sul/epidemiologia , Espectinomicina/uso terapêutico , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/epidemiologia , Infecções Estafilocócicas/microbiologia , Staphylococcus/efeitos dos fármacos , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Tilosina/uso terapêutico
18.
J Dermatol ; 44(4): 401-405, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-27743393

RESUMO

The standard management of acne vulgaris in Japan includes a combination of topical treatment with benzoyl peroxide (BPO) and BPO/clindamycin (CLDM), topical adapalene and systemic antimicrobials. However, the treatment of therapy-resistant complications such as postinflammatory hyperpigmentation (PIH), erosions with inflamed red papules and atrophic scars has not been established. We performed chemical peeling with glycolic acid and iontophoresis with ascorbyl 2-phosphate 6-palmitate and DL-α-tocopherol phosphate for the treatment of PIH, erosions with inflamed red papules and non-inflamed atrophic scars in 31 patients with acne vulgaris (mild to severe severity), and evaluated the efficacy and safety of these interventions. In most of cases, there was remarkable improvement in PIH and erosions with inflamed red papules after treatment. There was also some improvement in non-inflamed atrophic scars without erythema. Mild redness and irritation was observed in four cases as adverse reactions. Early initial treatment of PIH and erosions with red papules by chemical peeling and iontophoresis is an effective and safe method to prevent the formation of atrophic scars in patients with acne vulgaris.


Assuntos
Acne Vulgar/complicações , Acne Vulgar/terapia , Abrasão Química/efeitos adversos , Cicatriz/terapia , Eritema/terapia , Hiperpigmentação/terapia , Iontoforese/efeitos adversos , Adapaleno/uso terapêutico , Adolescente , Adulto , Anti-Infecciosos/uso terapêutico , Ácido Ascórbico/administração & dosagem , Ácido Ascórbico/efeitos adversos , Ácido Ascórbico/análogos & derivados , Ácido Ascórbico/uso terapêutico , Atrofia , Peróxido de Benzoíla/uso terapêutico , Cicatriz/patologia , Clindamicina/uso terapêutico , Terapia Combinada , Feminino , Glicolatos/administração & dosagem , Glicolatos/efeitos adversos , Glicolatos/uso terapêutico , Humanos , Japão , Masculino , Índice de Gravidade de Doença , Resultado do Tratamento , Adulto Jovem , alfa-Tocoferol/administração & dosagem , alfa-Tocoferol/efeitos adversos , alfa-Tocoferol/análogos & derivados , alfa-Tocoferol/uso terapêutico
19.
J Med Assoc Thai ; 100(1): 78-85, 2017 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29911775

RESUMO

Background: Treatments of acne vulgaris commonly use antimicrobials and comedolytic agents. Considering bacterial resistance to topical antibiotics, the alternative treatment such as silver manufactured into nanoparticle receives an attention. Silver nanoparticle has an antibacterial effect against Propionibacterium acnes and anti-inflammation. Clinical study of silver nanoparticle gel for the treatment of acne vulgaris is limited. Objective: To compare the efficacy and safety between silver nanoparticle gel and 1% clindamycin gel both combine with 2.5% benzoyl peroxide for the treatment of moderate severity of acne vulgaris. Material and Method: This was an experimental, double-blinded, randomized-controlled study. Sixty-four moderately severe acne patients were enrolled. They were randomized to receive either silver nanoparticle gel with 2.5% benzoyl peroxide or clindamycin gel with 2.5% benzoyl peroxide (32 patients each). The clinical outcomes were evaluated for inflammatory and non-inflammatory acne count, acne redness, the patients' satisfaction and patients' Dermatology Life Quality Index (DLQI) at the baseline, 2, 4, 6 and 8-week visit. Results: After 8 weeks of follow-up period, the average mean percent change from the baseline of non-inflammatory and inflammatory acne counts were gradually declined in both silver nanoparticle and clindamycin group. At the study endpoint (8-week visit), average mean percent change from the baseline of inflammatory acne count was slightly better reduction in silver nanoparticle group (79.7%) than clindamycin group (72.6%) with no significant difference (p = 0.18). The average mean percent change from the baseline of non-inflammatory acne count reduction was also no difference from silver nanoparticle and clindamycin group (61.1% and 66.8% respectively, p = 0.22). For clinical erythema score and Mexameter erythema index to evaluate acne redness were no statistical difference between the 2 groups. Moreover, the patients' satisfaction to study medication and their quality of life of patients (DLQI score) were reported with better improvement from the baseline in both groups but there was no statistical significant difference. Except for average mean, patients' satisfaction to acne severity at 6-week visit showed that silver nanoparticle group had better satisfaction score than clindamycin group (4.6±0.6 vs. 4.2±0.6) with statistical significance (p = 0.01). Common adverse effects were skin dryness (28.1%) and skin irritation (4.7%) which might be caused by 2.5% benzoyl peroxide. There was no adverse effect for silver nanoparticle gel from the present study. Conclusion: Silver nanoparticle gel is effective with good safety profile for the treatment of acne vulgaris. The present study demonstrated that there were no clinical significant differences between silver nanoparticle gel and clindamycin gel for the treatment of moderate severity of acne vulgaris when use in combination with 2.5% benzoyl peroxide. The clinical application as alternative treatment for acne is advised.


Assuntos
Acne Vulgar/tratamento farmacológico , Antibacterianos/uso terapêutico , Peróxido de Benzoíla/uso terapêutico , Clindamicina/uso terapêutico , Nanopartículas Metálicas/uso terapêutico , Adulto , Antibacterianos/administração & dosagem , Clindamicina/administração & dosagem , Método Duplo-Cego , Quimioterapia Combinada/métodos , Feminino , Seguimentos , Géis , Humanos , Masculino , Satisfação do Paciente , Qualidade de Vida , Prata/uso terapêutico , Resultado do Tratamento , Adulto Jovem
20.
Eur J Paediatr Dent ; 18(4): 285-290, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29380613

RESUMO

AIM: To compare the clinical and radiographic success rates of an antibiotic mix consisting of metronidazole, minocycline and ciprofloxacin (3Mix-MP) and another mix where minocycline was replaced with clindamycin (3Mix-MP-R) in non-instrumentation endodontic treatment (NIET) of necrotic primary molars and to determine the effect of root resorption on the success of the treatment. MATERIALS AND METHODS: Forty-two necrotic mandibular primary molars from 22 healthy children were randomly assigned to either mixture. Blinded clinical evaluation was conducted after 1, 3, 6 and 12 months by the operator, and blinded radiographic evaluation was conducted at 6 and 12 months follow-ups by other two investigators with inter-examiner reproducibility of 0.95. RESULTS: Overall success rates of 3Mix-MP and 3Mix-MP-R were 80.96% and 76.20% respectively, with no statistically significant difference. Radiographically, resorption of more than one third of the root length had a lower failure rate with no statistically significant difference (p<0.5). CONCLUSION: Primary teeth with necrotic pulp can be treated with 3Mix-MP or 3Mix-MP-R irrespective of the degree of root resorption.


Assuntos
Antibacterianos/uso terapêutico , Necrose da Polpa Dentária/diagnóstico por imagem , Necrose da Polpa Dentária/terapia , Dente Molar/diagnóstico por imagem , Criança , Ciprofloxacina/uso terapêutico , Clindamicina/uso terapêutico , Combinação de Medicamentos , Feminino , Humanos , Masculino , Metronidazol/uso terapêutico , Minociclina/uso terapêutico , Reprodutibilidade dos Testes , Materiais Restauradores do Canal Radicular/uso terapêutico , Reabsorção da Raiz , Dente Decíduo , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA